Maria Siano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Siano has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Gennaro Ilardi
Pathology Unit, Department of Advanced Biomedical Sciences, University of Naples Federico II, Via S. Pansini, 5, 80131 Napoli, Italy
5 shared publications - Stefania Staibano
Pathology Unit, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy
3 shared publications - Francesco Merolla
Department of Medicine and Health Sciences “V. Tiberio”, University of Molise, 86090 Campobasso, Italy
2 shared publications - Gaetano De Rosa
Department of Biomorphological and Functional Sciences, Pathology Section
2 shared publications - Massimo Mascolo
Department of Advanced Biomedical Sciences, Unit of Pathology University of Naples Federico II Naples Italy
2 shared publications - Alfredo Fusco
Institute of Experimental Endocrinology and Oncology (IEOS) “G. Salvatore”, National Research Council (CNR), Via Sergio Pansini 5, 80131 Naples, Italy
1 shared publication
Latest Publications
- RetractedOpen Access
- 24 September 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 433
RETRACTED ARTICLE: Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors
DNA damage response has been clearly described as an anti-cancer barrier in early human tumorigenesis. Moreover, interestingly, testicular germ cell tumors (TGCTs) have been reported to lack the DNA Damage Response (DDR) pathway activation.
- 24 September 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 433
RetractedOpen AccessRETRACTED ARTICLE: Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors
DNA damage response has been clearly described as an anti-cancer barrier in early human tumorigenesis. Moreover, interestingly, testicular germ cell tumors (TGCTs) have been reported to lack the DNA Damage Response (DDR) pathway activation.
- 29 July 2013
- Published by Springer Nature
- p. 161-182
Gene Polymorphisms
- 29 July 2013
- Published by Springer Nature
- p. 195-200
Mapping Prostate Cancer Aggressiveness Loci
- Open Access
- 21 February 2012
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 13 (2) , 2331-2353
Epigenetic Disregulation in Oral Cancer
Squamous cell carcinoma of the oral region (OSCC) is one of the most common and highly aggressive malignancies worldwide, despite the fact that significant results have been achieved during the last decades in its detection, prevention and treatment. Although many efforts have been made to define the molecular signatures that identify the clinical outcome of oral cancers, OSCC still lacks reliable prognostic molecular markers. Scientific evidence indicates that transition from normal epithelium to pre-malignancy, and finally to oral carcinoma, depends on the accumulation of genetic and epigenetic alterations in a multistep process. Unlike genetic alterations, epigenetic changes are heritable and potentially reversible. The most common examples of such changes are DNA methylation, histone modification, and small non-coding RNAs. Although several epigenetic changes have been currently linked to OSCC initiation and progression, they have been only partially characterized. Over the last decade, it has been demonstrated that especially aberrant DNA methylation plays a critical role in oral cancer. The major goal of the present paper is to review the recent literature about the epigenetic modifications contribution in early and later phases of OSCC malignant transformation; in particular we point out the current evidence of epigenetic marks as novel markers for early diagnosis and prognosis as well as potential therapeutic targets in oral cancer.
- 21 February 2012
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 13 (2) , 2331-2353
Open AccessEpigenetic Disregulation in Oral Cancer
Squamous cell carcinoma of the oral region (OSCC) is one of the most common and highly aggressive malignancies worldwide, despite the fact that significant results have been achieved during the last decades in its detection, prevention and treatment. Although many efforts have been made to define the molecular signatures that identify the clinical outcome of oral cancers, OSCC still lacks reliable prognostic molecular markers. Scientific evidence indicates that transition from normal epithelium to pre-malignancy, and finally to oral carcinoma, depends on the accumulation of genetic and epigenetic alterations in a multistep process. Unlike genetic alterations, epigenetic changes are heritable and potentially reversible. The most common examples of such changes are DNA methylation, histone modification, and small non-coding RNAs. Although several epigenetic changes have been currently linked to OSCC initiation and progression, they have been only partially characterized. Over the last decade, it has been demonstrated that especially aberrant DNA methylation plays a critical role in oral cancer. The major goal of the present paper is to review the recent literature about the epigenetic modifications contribution in early and later phases of OSCC malignant transformation; in particular we point out the current evidence of epigenetic marks as novel markers for early diagnosis and prognosis as well as potential therapeutic targets in oral cancer.
- Open Access
- 24 February 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 63
Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients
Cutaneous melanoma (CM) is the most lethal form of skin malignancy, which registers a constant increase in incidence worldwide. The identification of molecular alteration(s) involved in its biological aggressiveness represents a major challenge for researchers, considering that existing therapies are ineffective to treat metastasizing cases. The epigenetic control of chromatin dynamics during DNA synthesis, replication, and repair is fundamental for the orderly progression of cell proliferation. The Chromatin Assembly Factor 1 (CAF-1) complex acts as a major regulator of this process; its intermediate (p60) subunit has been recently proposed as a novel proliferation and prognostic marker for several tumors. We aimed to establish if the evaluation of the expression of CAF-1/p60 in primary CM may help define the prevision of outcome of patients.
- 24 February 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 63
Open AccessOverexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients
Cutaneous melanoma (CM) is the most lethal form of skin malignancy, which registers a constant increase in incidence worldwide. The identification of molecular alteration(s) involved in its biological aggressiveness represents a major challenge for researchers, considering that existing therapies are ineffective to treat metastasizing cases. The epigenetic control of chromatin dynamics during DNA synthesis, replication, and repair is fundamental for the orderly progression of cell proliferation. The Chromatin Assembly Factor 1 (CAF-1) complex acts as a major regulator of this process; its intermediate (p60) subunit has been recently proposed as a novel proliferation and prognostic marker for several tumors. We aimed to establish if the evaluation of the expression of CAF-1/p60 in primary CM may help define the prevision of outcome of patients.